Physician profile
Dhruva Kumar
NPI 1871524322
$5,739.16
in general payments reported to CMS, 2019-2025
27 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $189 · 2021: $276 · 2022: $750 · 2023: $1,131 · 2024: $1,438 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,948.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,064.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $955.60 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $568.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $461.36 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $346.00 | 2022-2025 | |
| Abbvie INC. | $302.02 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $277.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $274.15 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Mylan Specialty L.P. | $205.42 | 2022-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.00 | 2019-2025 | Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $185.98 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $131.10 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.14 | 2020-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $97.44 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $93.14 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $85.08 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $82.36 | 2024-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $72.29 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.28 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $43.28 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $30.24 | 2024-2025 | Voquezna |
| Seqirus USA INC | $21.96 | 2025 | Flucelvax, Fluad |
| Lundbeck LLC | $14.91 | 2025 | Rexulti |
| Abbott Laboratories | $14.29 | 2022 | |
| Eisai INC. | $14.19 | 2024 | |
| Exact Sciences Corporation | $14.19 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhruva Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.